Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Age
55–100
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Subject has provided informed consent prior to any study-specific activities/procedures
Ambulatory postmenopausal women.
Age 55 years or older
Screening BMD value equivalent to a T-score less than or equal to -2.5 at the lumbar spine, total hip, or femoral neck.
You may not be if
Administration of osteoporosis treatments or bone active treatments within specific timeframes
Vitamin D deficiency
Diseases and conditions that affect bone metabolism (e.g., hypo/hyper-parathyroidism; hypo/hyperthyroidism, unless stable and well-controlled)
Contraindications to denosumab therapy (e.g., hypocalcemia)
Clareo Health | A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis
